LitCovid-sentences  

PMC:7600245 / 11363-14062 JSONTXT 7 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T84 0-353 Sentence denotes As far as clinical trials in humans, a randomized, placebo-controlled, double-blind trial in hospitalized adults (n = 236) with severe COVID-19 in China initially revealed that the median time to improvement was not substantially different in the remdesivir group (200 mg on the first day, and then 100 mg/day for 9 days) from that of the placebo group.
T85 354-413 Sentence denotes The mortality rate was also similar in the two groups [37].
T86 414-477 Sentence denotes Yet, the trial was criticized for being insufficiently powered.
T87 478-756 Sentence denotes Later, a phase 3 randomized, open-label trial in adults (n = 397) hospitalized with severe COVID-19 sponsored by Gilead revealed that the time to clinical improvement for 50% of patients was 10 days in the 5-day treatment group relative to 11 days in the 10-day treatment group.
T88 757-849 Sentence denotes The dose regimen used was 200 mg on day 1, followed by 100 mg/day for total of 5 or 10 days.
T89 850-981 Sentence denotes At day 14, about 64.5% of the patients in the 5-day group and 53.8% of the patients in the 10-day group achieved clinical recovery.
T90 982-1140 Sentence denotes Patients treated with remdesivir within 10 days of symptoms onset achieved better outcomes relative to those treated after more than 10 days of symptoms [38].
T91 1141-1242 Sentence denotes Similar results were obtained in hospitalized adults (n = 1600) with moderate COVID-19 (NCT04292730).
T92 1243-1385 Sentence denotes In an uncontrolled study of hospitalized COVID-19 patients (n = 61), most patients needed less oxygen support after receiving remdesivir [39].
T93 1386-1477 Sentence denotes Importantly, a phase 3 adaptive, randomized, placebo-controlled study sponsored by the U.S.
T94 1478-1843 Sentence denotes National Institute of Allergy and Infectious Diseases (NIAID) in hospitalized adults (n = 1063) indicated that: (a) the patients in the remdesivir group had shorter median time to recovery (11 days) than the patients in the placebo group (15 days) and (b) remdesivir may decrease the mortality rate from 11.6% in the placebo group to 8% in the treatment group [40].
T95 1844-1906 Sentence denotes As of now, the COVID-19 Treatment Guidelines Panel of the U.S.
T96 1907-2133 Sentence denotes National Institute of Health recommends remdesivir for the treatment of COVID-19 in hospitalized patients with severe disease (requiring supplemental oxygen or on mechanical ventilation or extracorporeal membrane oxygenation).
T97 2134-2298 Sentence denotes The Panel also indicates that there are no sufficient data to recommend either for or against the use of remdesivir in patients with mild or moderate COVID-19 [41].
T98 2299-2316 Sentence denotes Of note, the U.S.
T99 2317-2521 Sentence denotes FDA warns against the concomitant use of remdesivir and chloroquine or hydroxychloroquine owing to in vitro evidence which suggests that chloroquine blocks the intracellular activation of remdesivir [42].
T100 2522-2699 Sentence denotes Moreover, data from the manufacturer’s compassionate use program suggested no safety concerns were identified for remdesivir in pediatric, pregnant, or postpartum patients [43].